< Agent Blog
Aug
14
,
2024

Excellus BCBS Broker News Vol. 19 No. 8 Special Issue

August 14, 2024
Excellus BlueCross BlueShield

A Message from Mona Chitre

As we look to the rest of the 2024 plan year, I wanted to take a moment to share all that has been happening in the pharmacy space and reiterate our mission to provide greater access to high-quality health care. As supporters of your business and clients, we continuously monitor and evaluate market information to make sure we are tailoring our programs and developing innovative solutions to meet their needs.

Below are highlights of our pharmacy updates this year and links to additional articles to provide you more information.

2024 Pharmacy Updates

  • Biosimilars: To date, there have been 57 biosimilar approvals and 38 launches in the U.S. market1 , which is good news for groups and members. As new biosimilars enter the market, increased competition brings down the price of the biosimilar and reference product. We continually monitor these drugs for formulary optimization so we can promote the use of biosimilars when the overall net cost is lower than its biologic product. Our approach to biosimilars differs by drug or drug category. In some drug categories like oncology, we take a biosimilar-first approach and as a result of this, adoption of the biosimilars for Avastin®, Herceptin® and Rituxan® reached 75% of the market share within two years of launch and we have generated $30 million in savings for our customers. For other categories where the marketplace dynamics are more complex, we currently provide access to the biosimilars while still maintaining coverage of the innovator brand product. Along with our formulary strategy, our Value Based Payment (VBP) arrangements with our local health systems allow us to work collaboratively to encourage switching to biosimilars when appropriate.
  • Gene and Cell Therapy: Gene and cell therapy offer innovative treatment options for members but can present financial challenges for groups. The US cell and gene therapy market was valued at $3.22 billion in 2022 and is projected to reach $25.58 billion in 2028A . Knowing how rapidly these trends are increasing we are always looking for ways to ensure better cost management. At Excellus BCBS we uniquely manage each gene and cell therapy case by developing prior authorization criteria. Our policy development team assesses the therapy for medical necessity overall evaluating the drug's clinical efficacy, safety profile, and cost-effectiveness compared to alternative treatments. This creates balance between patient access and cost management.
  • Glucagon-Like Peptide-1 Agonists (GLP-1): Blue Health Intelligence® released new key findings on GLP-1 use for weight management. The data showed that 30% of patients stopped treatment within four weeks, before reaching the targeted dose3. This data further supports our Utilization Management efforts to provide an unbiased review for each request of a GLP-1 to confirm medical necessity and safety – protecting against inappropriate prescribing and wasteful spending. Currently, we are saving groups an average of $2.66 PMPM* through GLP-1 Utilization Management.
  • Medication Assurance Program**: Drugs approved via the Food and Drug Administration’s (FDA) Accelerated Approval pathway are often very expensive specialty medications. Unlike traditional FDA approved drugs, Accelerated Approval drugs have indications that have unconfirmed clinical benefit at the time of their approval. In response to this unique approval process, we have created the Medication Assurance program. This first-of-its-kind program is designed to ensure effectiveness and reduce spend of Accelerated Approval drugs through partnership with drug manufacturers. This innovative program helps ensure there is value aligned with drugs approved through the FDA’s Accelerated Approval process.
  • Smart RxAssist**: Starting 7/1/2024, Excellus BCBS has partnered with HealthSmart to offer a medical specialty copay assistance program known as Smart RxAssist (SRxA). SRxA offers members and groups the opportunity to reduce the financial burdens associated with specialty medications that are infused and injected by a physician, home infusion provider or infusion center and billed under the medical benefit. Similarly, as a pharmacy benefit, we have SaveOnSP**, a program providing financial relief for certain specialty prescription drugs. We have already seen positive results from this program with net savings of $14.8 million for our commercial book of business in 2023.

Wishing you all a great rest of the year, Mona Chitre, CPO & President of Pharmacy Solutions

1 Center for Drug Evaluation and Research. “Biosimilar Drug Information.” U.S. Food and Drug Administration, 2019, www.fda.gov/drugs/biosimilars/biosimilar-product-information.

A ltd, R. and M. (n.d.). US Cell & Gene Therapy Market - Focused Insights 2023-2028. www.researchandmarkets.com. Retrieved July 2, 2024, from www.researchandmarkets.com/reports/5806791/us-cell-and-gene-therapy-market-focused-insights

3 Blue Health Intelligence. “Real-World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management”, May 2024, Issue Brief May 2024: Real-world trends in GLP-1 treatment persistence and prescribing for weight management (bcbs.com) (PDF)

* Health Plan Commercial Rx Book of Business (BoB) Data, these are averages based on BoB data and are not guarantees.

** Available to our self-funded groups, excluding minimum premium and article 47 groups

View Details >View Details >

Questions? Call us at 855-888-8326.

Don't have a MedCareValue page yet?

Get Your FREE Site >

Posts you may be interested in...

Read More

VBE programs for HRA, email, and PCP assignment

October 10, 2024
Agent Blog Icon - Indicates this is a blog article.

Cigna is continuing their Value Based Enrollment (VBE) program including VBE payments for health risk assessments (HRAs) and digital application submissions.

Read More

NOW LIVE! New personalized marketing materials

October 9, 2024
Agent Blog Icon - Indicates this is a blog article.

These pieces are designed to help you connect with your clients more effectively and prepare you for a successful year ahead.

Read More

Florida Blue Medicare Spotlight: RPPO Exit and PPO Migration Opportunities

October 8, 2024
Agent Blog Icon - Indicates this is a blog article.

Important Updates on RPPO Exit and Migration Opportunities: Help members transition from RPPO to LPPO plans

Read More

Sunfire HRAs and important Agent Portal updates from Devoted Health

October 8, 2024
Agent Blog Icon - Indicates this is a blog article.

AEP has arrived and Devoted Health is excited to share some updates about Sunfire HRAs, Medicaid check availability, plan change applications, and the provider search tool in their Agent Portal.

Read More

Have you heard? Digital sales kits are available this AEP from Cigna

October 7, 2024
Agent Blog Icon - Indicates this is a blog article.

Cigna is now offering a digital sales kit solution for AEP 2025.

Read More

UnitedHealthcare: JarvisWRAP for October 7

October 7, 2024
Agent Blog Icon - Indicates this is a blog article.

Part D and 2025 plan member education resources now available

Who we are & what we do.

Choosing an FMO to work with is not just about having access to top insurance products and commissions, it’s about finding a one-on-one agent service that is prepared to meet your needs.  

Get to know us, and see how we can help you take your business to the next level.

Learn More

Helpful Links

New Here?

We love meeting new people! Fill out the form below, and one of our sales directors will get in touch with you shortly.

Thank you! Your form has been received!
Oops! Something went wrong while submitting the form